| Similar Articles |
|---|
 |
Bio-IT World
August 13, 2003
Branca et al. |
Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising.   |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one. |
Bio-IT World
November 19, 2004
Hoffer & Nambiar |
Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004. |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
The Motley Fool
January 7, 2011
Brian Orelli |
A Biotech Roller Coaster Lexicon is back on the upswing. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
Bio-IT World
May 9, 2003
Malorye Branca |
Discovering the Joy of Cannibalism Persistent financial pressures feed continuing consolidation among struggling genomics companies |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
June 22, 2004
Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
August 4, 2010
Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
Bio-IT World
September 2005
Mark D. Uehling |
Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms. |
The Motley Fool
December 14, 2010
Travis Hoium |
Lexicon Pharmaceuticals Shares Plunged: What You Need to Know Lexicon Pharmaceuticals shares fell as much as 14% in intraday trading on disappointing results of its rheumatoid arthritis drug test. |
The Motley Fool
February 2, 2007 |
Vetting Vertex Pharmaceuticals: Fool by Numbers The pharmaceutical released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 9, 2006
Brian Lawler |
Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note. |
The Motley Fool
December 27, 2007
Brian Lawler |
A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma. |
Pharmaceutical Executive
July 1, 2006
Deborah Dunsire |
Thoughtleader: Targeted Expansion Millennium Pharmaceuticals' CEO discusses what's ahead for the company, its success through partnerships, and why it believes it can lead the pack in targeted therapeutics. |
The Motley Fool
April 30, 2007
Brian Lawler |
The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note. |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
The Motley Fool
May 17, 2011
Luke Timmerman |
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. |
The Motley Fool
July 10, 2009
Brian Orelli |
Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders. |
The Motley Fool
December 11, 2006
Dan Caplinger |
Index Funds: So Hot Right Now Indexing is stylish, but can you profit from its idiosyncrasies? |
